CD274 and esophageal squamous cell carcinoma: In advanced esophageal squamous cell cancer (ESCC), pembrolizumab, a monoclonal antibody targeting PD-L1, has been approved by the United States Food and Drug Administration (FDA) and significantly improves patient survival rates [21].